1599529-80-2

Basic information

• Product Name: 6-bromo-3-((6-(trifluoromethyl)pyridin-3-yl)methyl)quinoline-2,4-diol
• CAS NO: 1599529-80-2
• Molecular Weight: 399.167
• Mol File: 1599529-80-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 6-bromo-3-((6-(trifluoromethyl)pyridin-3-yl)methyl)quinoline-2,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-3-((6-(trifluoromethyl)pyridin-3-yl)methyl)quinoline-2,4-diol(1599529-80-2)
• EPA Substance Registry System: 6-bromo-3-((6-(trifluoromethyl)pyridin-3-yl)methyl)quinoline-2,4-diol(1599529-80-2)

Safety Data

• Hazardous Substances Data: 1599529-80-2(Hazardous Substances Data)

Upstream product

• 106-40-1 4-bromo-aniline 
• 95262-09-2 3-[(4-bromophenyl)amino]-3-oxopropanoic acid 
• 54675-23-9 6-bromo-4-hydroxyquinoline-2(1H)-one 
• 386704-12-7 6-(trifluoromethyl)pyridine-3-carbaldehyde 

Relevant articles and documents

SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of FormulaI.wherein:R1, R2, R3, R4, R5, R6, R7, R8, and R9are defined in the specification.The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.